Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Merck & Co., Inc. (MRK) Guidance & Earnings Results

On 2026-04-30 Merck & Co., Inc. raised guidance: "Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS raised to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MRKMerck & Co., Inc.Follow MRK — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
358.4B
P/E TTM
115.3
Dividend yield
2.3%
52-week
—
Next earnings
29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
30 Apr 26RaisedFull-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS raised to $5.04-$5.16 · full year

Merck & Co., Inc. — questions

What guidance did Merck & Co., Inc. give?
On 2026-04-30: "Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS raised to $5.04-$5.16"
When does Merck & Co., Inc. report earnings?
Merck & Co., Inc.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from Merck & Co., Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.